Linagliptin in Combination with Emblica officinalis Gaertn Improves Glycemic Control through Alleviating Dyslipidemia and Oxidative Stress on Streptozotocin Induced Diabetic Rats

Abstract

Objectives: Diabetes is a complex chronic metabolic disorder. Today, many diabetes patients are known to supplement their standard therapies with herbal medications that have antidiabetic characteristics. The purpose of the study was to examine the fixed dose combination of linagliptin and Emblica officinalis Gaertn (aq FE) for its hypoglycemic, hypolipidemic, and antioxidant properties.
 Methods: Streptozotocin (45 mg/kg b.w.) was administered intraperitoneally to Wister albino rats to cause diabetes. Linagliptin (5 mg/ 70kg b.w), aqueous fruit extract of Emblica officinalis Gaertn (200 mg/kg b.w.) and fixed dose combination therapy of linagliptin (2.5 mg /70kg b.w) with aqueous fruit extract of Emblica officinalis Gaertn (100 mg/kg b.w) were administered orally once daily for four weeks. After that fasting blood glucose level (FBG), low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (TC) and triglycerides (TG) were measured in serum with streptozotocin (STZ)-induced diabetes. Typical procedures were used to measure the antioxidant activity by the estimation of catalase (CAT) and superoxide dismutase (SOD) activity.
 Results: The combination therapy significantly (p<0.05) reduced the FBG, TC, TG, LDL level in compared to the diabetic control group (p<0.05). Significant (p<0.05) increased of HDL was also observed. The antioxidant activity significantly increased after the administration of fixed dose combination therapy in compared to diabetic control group. These alterations were vastly superior to those of linagliptin with Emblica officinalis Gaertn (aqFE) monotherapy.
 Conclusion: This study suggests that the fixed dose combination therapy of linagliptin and Emblica officinalis Gaertn (aq FE) might be potent on antihyperglycemic antidyslipidemic and antioxidative effect.